CareDx Reports Q4 Revenue Growth and European Launch of AlloSure Test
CareDx held its Q4 2025 earnings call on Feb. 25 and reported year-over-year revenue growth alongside a strategic rollout of its AlloSure transplant surveillance test into key European markets. Management detailed margin expansion, outlined operating expense reduction targets and reaffirmed its full-year 2026 financial guidance.
1. Q4 2025 Financial Results
CareDx opened its Feb. 25 call by noting a year-over-year increase in Q4 revenue driven by higher test volumes and improved service adoption. The company emphasized stronger contribution from its core transplant diagnostics offerings.
2. AlloSure European Expansion
Executives announced the initial commercial launch of the AlloSure test in multiple European countries, aiming to broaden its global footprint in transplant surveillance. Preparations include local lab partnerships and regulatory filings to accelerate market entry.
3. Margin Improvement and Cost Initiatives
Management highlighted an expansion in gross margin compared to the prior year and outlined targets to reduce operating expenses through process optimization and technology investments. These measures are expected to drive improved profitability in 2026.
4. Reaffirmed 2026 Outlook
Despite macro uncertainty, CareDx reaffirmed its full-year 2026 revenue and profitability guidance, citing continued growth in its AlloSure platform and disciplined expense management to support long-term value creation.